Home > News and Events > Press Releases > content
The main structure of UBP’s new industrial-scale protein API facility was completed today
2016/03/12
 

United BioPharma (UBP, 6471) announced the completion of the main structure of it’s new protein manufacturing facility today (March 12).

UBP’s new facility broke ground in April 2015 and is expected to be certified and registered in September 2016. The large scale manufacture of UB-421 (UBP’s monoclonal antibody drug for AIDS) will begin in 2017 and that product will be used in phase III clinical trials, pre-marketing process validation, and US FDA facility inspection. The growth of UBP will accelerate with the completion of new facility which offers capabilities for process development for the antibody drug pipelines, drug manufacturing for clinical trials, post-marketing manufacturing, and providing contract manufacturing services.

About United BioPharma (6471)

Founded in October 2013, United BioPharm (UBP) was spun-off from its parent company, United Biomedical, Inc., Asia, to focus on its monoclonal antibody drugs business. UBP has established a strategic partnership with Taiwan conglomerate, Formosa Plastics Group and its Chang-Gung Memorial Hospital network. UBP possesses a comprehensive technology platform for antibody drug development and is focused on the R&D, manufacture, and global commercialization of innovative monoclonal antibodies and biosimilar antibodies with significant market potential. Driven by innovation and execution, UBP strives to provide effective therapeutics to address unmet medical needs, improve human health and contribute to Taiwan’s economic development.

For additional information about the company, please visit http://www.unitedbiopharma.com


Contact: Victor Sun, VP of Business Administration and Spokesperson
Tel: 886-3-668-4800 ext 808
PR@unitedbiopharma.com

victor.sun@unitedbiopharma.com